MSI1 and neoplasm: As hypothesized, the therapeutic window was narrow, with few concentrations adequately targeting G3 MB whilst sparing NSC function (Supplementary Fig. 8b–e) suggesting a significant risk of on-target, off-tumor effects predicted from our in vitro results after inhibition of MSI1 in NSCs.